Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Assets (2018 - 2025)

Historic Current Assets for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $2.0 billion.

  • Revolution Medicines' Current Assets rose 2522.58% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2522.58%. This contributed to the annual value of $2.3 billion for FY2024, which is 2385.76% up from last year.
  • Revolution Medicines' Current Assets amounted to $2.0 billion in Q3 2025, which was up 2522.58% from $2.2 billion recorded in Q2 2025.
  • Revolution Medicines' Current Assets' 5-year high stood at $2.3 billion during Q4 2024, with a 5-year trough of $483.0 million in Q2 2022.
  • In the last 5 years, Revolution Medicines' Current Assets had a median value of $922.1 million in 2023 and averaged $1.2 billion.
  • Its Current Assets has fluctuated over the past 5 years, first plummeted by 2692.32% in 2022, then soared by 18465.98% in 2023.
  • Quarter analysis of 5 years shows Revolution Medicines' Current Assets stood at $589.8 million in 2021, then increased by 11.94% to $660.2 million in 2022, then surged by 184.66% to $1.9 billion in 2023, then increased by 23.86% to $2.3 billion in 2024, then decreased by 15.04% to $2.0 billion in 2025.
  • Its Current Assets stands at $2.0 billion for Q3 2025, versus $2.2 billion for Q2 2025 and $2.1 billion for Q1 2025.